Review: Low-molecular-weight heparin is more effective than unfractionated heparin for preventing reinfarction in STEMI

July 2006
ACP Journal Club;Jul/Aug2006, Vol. 145 Issue 1, p9
Academic Journal
The article presents a study which states that for the prevention of reinfarction in ST-elevation acute myocardial infarction low-molecular-weight heparin (LMWH) is more effective than unfractionated heparin (UFH). As compare to the UFH group, LMWH group has lower chances of myocardial infarction (MI) and a higher incidence of minor or major bleeding. Both the groups did not differ for mortality, major bleeding and stroke. The LMWH group had a lower incidence of MI and death in comparison with placebo, but has a higher incidence of minor and major bleeding.


Related Articles

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...

  • Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI. Berger, Peter B. // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p11 

    This article presents a study related to effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction (MI) presenting with ST-segment elevation. Several patients were presented with suspected acute MI and ST-segment...

  • Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. Suzuki, Shunji; Sakamoto, Susumu; Okada, Takeaki; Matsuo, Miyako; Saitoh, Atsushi; Matsuo, Takefumi // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p341 

    A patient with systemic lupus erythematosus and anti-cardiolipin antibodies and antibodies to platelet factor 4/heparin complexes suffered an acute myocardial infarction caused by delayed heparin-induced thrombocytopenia after heparin administration given to treat pulmonary hypertension....

  • ANTICOAGULANT THERAPY TODAY. Vigran, I. Myron // Angiology;Jan1964, Vol. 15 Issue 1, p1 

    A review has been presented of some of the more classical and recent findings in regard to results of anticoagulant therapy in acute myocardial infarction, the long-term prophylactic treatment of coronary artery disease, the use of anticoagulant therapy in cerebral vascular disease, as well as...

  • Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction. Carter, Natalie J.; McCormack, Paul L.; Plosker, Greg L. // BioDrugs;2008, Vol. 22 Issue 5, p343 

    Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention. It binds to and...

  • Review: Low-molecular-weight heparin is effective and safe in the acute coronary syndromes.  // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58 

    This article focuses on the usage of low-molecular-weight heparins (LMWH) in the management of acute coronary artery syndromes (ACS) and percutaneous coronary intervention. Selected studies have included randomized controlled trials that have compared LMWH with unfractionated heparin (UFH) or...

  • Review: Low-molecular-weight herapin is effective and safe in the acute coronary syndromes: COMMENTARY. Hillegass, William B.; Brott, Brigitta C. // ACP Journal Club;Nov/Dec2003, Vol. 139 Issue 3, p58 

    Researcher G.C. Wong and colleagues have provided a systematic review of trials comparing low molecular weight heparin (LMWH) and un-fractionated heparin (UFH) in patients with acute coronary syndrome (ACS). In patients with unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI),...

  • Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease*. Hinder, Markus; Frick, Annke; Jordaan, Pierre; Hesse, Galina; Gebauer, Alexander; Maas, Jochen; Paccaly, Anne // Clinical Pharmacology & Therapeutics;Dec2006, Vol. 80 Issue 6, p691 

    Background: New anticoagulants that combine effective anticoagulation with low bleeding rates are still sought after. We investigated the safety, pharmacokinetics, and pharmacodynamics of otamixaban, a direct factor Xa inhibitor, in patients with stable coronary artery disease.Methods: This was...

  • PRIMARY ANGIOPLASTY OR T-PA FOR THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION? Bailey, Gene; Flynn, Cheryl A. // Journal of Family Practice;Aug1999, Vol. 48 Issue 8, p577 

    The article presents information on a study that compared the efficacy of primary angioplasty and tissue-type plasminogen activator (t-PA) in managing acute myocardial infarction. A total of 395 patients were enrolled in the study between June 1990 and April 1992. Patients of any age presented...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics